Skip to main content

Molecular mechanism of protein-protein and membrane-protein interactions in cellular processes.

RYC2018-023837-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of a new selective ligand for targeting neuronal KV4.3/KChIP3 over cardiac KV4.3/KChIP2 channels

  • Socuellamos, Paula G.
  • Viedma-Barba, Carmen
  • de Benito-Bueno, Angela
  • Bonache de Marcos, María Ángeles
  • Ropero, Maria
  • Diez, Sara
  • Elizalde, Pablo
  • Marín-Olivero, Irene
  • Redondo-Moya, Maria
  • Naranjo, Jose Ramon
  • Gonzalez-Vera, Juan A.
  • Orte, Angel
  • Perez-Lara, Angel
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
The present study aimed to discover novel KChIP ligands as pharmacological tools for modulating the KV4.3/KChIP channels. A multidisciplinary approach, combining medicinal chemistry and electrophysiology studies, led to the successfully identification of a novel KV4.3/KChIP modulator (IQM-22110). Its design was guided by the previous knowledge of the (phenylacetamido)benzoic acid moiety as suitable scaffold, along with virtual screening of a focused chemical library that suggested improved KChIP3 binding upon incorporation of an additional aromatic ring. IQM-22110 was selected for synthesis and identified as a potent KChIP3 ligand. Its electrophysiological effects on KV4.3/KChIP3 currents indicate that IQM-22110 binds to a high affinity site in KV4.3/KChIP3 channels that it is not present in KV4.3/KChIP2 or KV4.3. To the best of our knowledge, here we describe the first KChIP3 ligand that selectively modulates KV4.3/KChIP3 versus KV4.3/KChIP2 and KV4.3 channels at nanomolar concentration. Since KChIP2 is predominantly expressed in cardiac tissue, this selectivity may enable the development of KV4.3/KChIP3-targeted therapeutics with reduced risk of cardiac side effects. Computational and site-directed mutagenesis studies allowed the identification of IQM-22110's binding site on KChIP3. Knowledge gained from structural and functional studies with this novel KChIP3 ligand could establish the basis for drug discovery programs fostering treatments for diseases in which KV4.3/KChIPs channels are involved., This work has been funded by grants: PID2022-137214OB-C21 (to CV) and PID2022-137214OB-C22 (to MG-R) funded by MCIN/AEI/h ttps://doi.org/10.13039/501100011033 and by “ERDF A way of mak ing Europe”; PID2023-148243OB-I00 AEI/https://doi.org/10.13039/ 501100011033 (to AO); Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to C.V.); CSIC grants 202580E109 (to MMM and MG-R) and 2023AEP049 (to CV); P. G. Socuéllamos was funded by FPU17/02731 granted by Spanish Minister of Science and Innovation. C. Viedma-Barba holds a FPI Predoctoral contracts subsidized by Spanish Minister of Science and Innovation (PRE2020-093542) granted by MCIN/AEI/https://doi.org/10.13039/501100011033 and “ESF Invest ing in your future”. A. de Benito-Bueno holds a FPI grant BES- 2017–080184. M. Redondo holds a FPI Contract subsidized by Spanish Minister of Science and Innovation (PREP2022-000706). A.P.-L. ac knowledges funding by a Ramon y Cajal grant (RYC2018-023837-I) and Max Planck Society through the funding of a Max Planck Partner Group on “Regulation of the SNARE zippering by complexins and synapto tagmins” at the University of Granada. We thank Centro de Supercomputaciónn de Galicia (CESGA) and Centro Técnico de Informática, CTI-CSIC for computer time at FinisTerrae III and DRAGO, respectively., Peer reviewed